A new trading day began on Tuesday, with Travere Therapeutics Inc (NASDAQ: TVTX) stock price down -3.09% from the previous day of trading, before settling in for the closing price of $38.88. TVTX’s price has ranged from $12.91 to $42.13 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -3.34%. Meanwhile, its annual earnings per share averaged 89.88%. With a float of $87.73 million, this company’s outstanding shares have now reached $89.46 million.
Travere Therapeutics Inc (TVTX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.94%, while institutional ownership is 116.70%. The most recent insider transaction that took place on Dec 24 ’25, was worth 199,200. In this transaction CHIEF COMMERCIAL OFFICER of this company sold 4,980 shares at a rate of $40.00, taking the stock ownership to the 113,013 shares. Before that another transaction happened on Dec 24 ’25, when Company’s Chief Research Officer sold 60,000 for $40.10, making the entire transaction worth $2,406,180. This insider now owns 101,443 shares in total.
Travere Therapeutics Inc (TVTX) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.47 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 89.88% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Here are Travere Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.08, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach 0.80 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Compared to the last year’s volume of 1.81 million, its volume of 1.88 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.69%.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 82.60%, which indicates a significant increase from 48.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.96 in the past 14 days, which was higher than the 1.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.12, while its 200-day Moving Average is $22.49. Nevertheless, the first resistance level for the watch stands at $38.71 in the near term. At $39.74, the stock is likely to face the second major resistance level. The third major resistance level sits at $40.48. If the price goes on to break the first support level at $36.94, it is likely to go to the next support level at $36.20. Now, if the price goes above the second support level, the third support stands at $35.17.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
With a market capitalization of 3.37 billion, the company has a total of 89,472K Shares Outstanding. Currently, annual sales are 233,180 K while annual income is -321,550 K. The company’s previous quarter sales were 164,860 K while its latest quarter income was 25,710 K.
